CORDIS
EU research results

CORDIS

English EN
Peptide-Drug Conjugates for Targeted Delivery in Tumor Therapy

Peptide-Drug Conjugates for Targeted Delivery in Tumor Therapy

Objective

Many tumor cells are characterized by the overexpression of certain antigens. Molecules that specifically recognize these structures are suitable as homing devices in tumor therapy. Conjugates of anticancer drugs with such a delivery vector targeting tumors would be a “magic bullet” according to the Nobel laureate Paul Ehrlich. Three antibody-drug conjugates (ADC) have already been approved for anticancer therapy. However, ADC have e.g. limitations with respect to tumor penetration, high manufacturing costs, and require challenging conjugation chemistry. Peptide-drug conjugates can have a high drug loading, easily penetrate tissue, and can be easily prepared in a homogenous form with straightforward and well-defined conjugation chemistry.
The ETN MAGICBULLET will focus on chemistry-driven approaches toward conjugates between peptides (delivery vectors) that recognize tumors and anticancer drugs (payloads or warheads) in order to selectively fight cancer, a topic with a high demand of research activities. The ETN will develop and validate an array of new peptide-drug conjugates combining either known tumor-specific peptides or newly discovered tumor-homing peptides with potent cytotoxic drugs. The tumor-selective peptides are designed for cellular uptake mediated either by endocytosis or by cell-penetrating peptides. The consortium of the ETN MAGICBULLET covers tumor biology, biochemistry, pharmacology, synthetic chemistry, medicinal chemistry, spectroscopy, conformational analysis, and computational chemistry.
The training program focuses on multidisciplinary research to explore and validate molecular targets for innovative treatment or investigations on the molecular mechanisms in organ-specific metastatic growth processes. It aims at scientific multilingualism and relies e.g. on concerted learning, a combination of introductory training, hands-on learning “on the bench”, teaching by peers, and training in additional skills.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITAET BIELEFELD

Address

Universitaetsstrasse 25
33615 Bielefeld

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 498 432,96

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITA DEGLI STUDI DELL'INSUBRIA

Italy

EU Contribution

€ 516 122,64

EOTVOS LORAND TUDOMANYEGYETEM

Hungary

EU Contribution

€ 447 827,04

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 538 290,72

UNIVERSITA DEGLI STUDI DI MILANO

Italy

EU Contribution

€ 516 122,64

UNIVERSITAET ZU KOELN

Germany

EU Contribution

€ 249 216,48

Orszagos Onkologiai Intezet

Hungary

EU Contribution

€ 223 913,52

HEIDELBERG PHARMA RESEARCH GMBH

Germany

EU Contribution

€ 498 432,96

EXIRIS SRL

Italy

EU Contribution

€ 258 061,32

Partners (5)

Sort alphabetically

Expand all

Bayer Pharma AG

FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN NUERNBERG

Kineto Lab Ltd.

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

IRBM SCIENCE PARK SPA

Project information

Grant agreement ID: 642004

Status

Closed project

  • Start date

    1 January 2015

  • End date

    31 December 2018

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 3 746 420,28

  • EU contribution

    € 3 746 420,28

Coordinated by:

UNIVERSITAET BIELEFELD

Germany